1. Academic Validation
  2. Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction

Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction

  • J Med Chem. 2014 Mar 27;57(6):2472-88. doi: 10.1021/jm401767k.
Ana Z Gonzalez 1 John Eksterowicz Michael D Bartberger Hilary P Beck Jude Canon Ada Chen David Chow Jason Duquette Brian M Fox Jiasheng Fu Xin Huang Jonathan B Houze Lixia Jin Yihong Li Zhihong Li Yun Ling Mei-Chu Lo Alexander M Long Lawrence R McGee Joel McIntosh Dustin L McMinn Jonathan D Oliner Tao Osgood Yosup Rew Anne Y Saiki Paul Shaffer Sarah Wortman Peter Yakowec Xuelei Yan Qiuping Ye Dongyin Yu Xiaoning Zhao Jing Zhou Steven H Olson Julio C Medina Daqing Sun
Affiliations

Affiliation

  • 1 Departments of †Therapeutic Discovery, ‡Pharmaceutics, and §Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.
Abstract

We previously reported the discovery of AMG 232, a highly potent and selective piperidinone inhibitor of the MDM2-p53 interaction. Our continued search for potent and diverse analogues led to the discovery of novel morpholinone MDM2 inhibitors. This change to a morpholinone core has a significant impact on both potency and metabolic stability compared to the piperidinone series. Within this morpholinone series, AM-8735 emerged as an inhibitor with remarkable biochemical potency (HTRF IC50 = 0.4 nM) and cellular potency (SJSA-1 EdU IC50 = 25 nM), as well as pharmacokinetic properties. Compound 4 also shows excellent antitumor activity in the SJSA-1 osteosarcoma xenograft model with an ED50 of 41 mg/kg. Lead optimization toward the discovery of this inhibitor as well as key differences between the morpholinone and the piperidinone series will be described herein.

Figures
Products